Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in children
https://doi.org/10.21518/2079-701X-2016-1-136-139
Abstract
Up to 60 thousand hematopoietic stem cell transplantations (HSCT) are carried out globally all over the world. The outcome of HSCT is largely determined by the probability and severity of the graft-versus-host reaction/disease (GVHD). Treatment involves corticosteroids. Antithymocyte globulin, extracorporeal photopheresis, monoclonal antibodies to interleukins or their receptors, methotrexate, cyclosporine, tacrolimus, sirolimus, antithymocyte globulin, etc. are used in steroid-refractory GVHD. It is worth to mention that mycophenolate mofetil, esther of mycophenolic acid, blocks proliferation of T and B lymphocytes. In patients who are refractory to corticosteroids, the use of mycophenolate mofetil in isolation or in combination with cyclosporine, tacrolimus seems to be justified.
About the Authors
Y. V. Skvortsova
Federal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev
Russian Federation
Russian Federation
D. N. Balashov
Federal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev
Russian Federation
Russian Federation
V. M. Delyagin
Federal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev
Russian Federation
Russian Federation
References
1. Скворцова Ю.В., Балашов Д.Н., Масчан М.А., Шелихова Л.Н., Масчан А.А. Динамическое наблюдение детей после аллогенной трансплантации гемопоэтических стволовых клеток. Российский журнал детской гематологии и онкологии, 2015. 2 (2): 50-59.
2. HoLLingsworth C, Frush D, Kurtzburg J, Vinod P. Pediatric Hematopoietic Stem CeLL Transplantation and the RoLe of Imaging. Radiology, 2008. 248 (2): 348-365.
3. Horowitz M. Uses and growth of hematopoietic ceLL transpLantation. In: Thomas' Hematopoietic CeLL TranspLantation, John WiLey & Sons, Inc. 2008. pp. 15-21.
4. Ruiz Ph. Pediatric Graft Versus Host Disease. http//emedicine.medscape.com/articLe/886758-overview Updated: Nov 22, 2013.
5. Barnes D, Loutit J, MickLem H. "Secondary disease" of radiation chimeras: a syndrome due to Lymphoid apLasia. Ann N Y Acad Sci. 1962. 99: 374-385.
6. BiLLingham R. The bioLogy of graft-versus-host reactions. Harvey Lect. 1966. 62: 21-78.
7. BaLL L, EgeLer R. Acute GvHD: pathogenesis and cLassification. Bone Marrow TranspLant. 2008. 41 SuppL 2: S58-64.
8. Sun Y, Tawara I, Toubai T, Reddy P. Pathophysio-Logy of acute graft-versus-host disease: recent advances. TransL Res. 2007. 150 (4): 197-214.
9. Stenger E, Rosborough B, Mathews L, Ma H, Mapara M, Thomson A, Turnquist M. IL-12hi Rapamycin-Conditioned Dendritic CeLLs Mediate IFN-?-Dependent Apoptosis of ALLoreactive CD4+ T CeLLs In Vitro and Reduce LethaL Graft-versus-Host Disease. BioL BLood Marrow TranspLant. 2013. 20 (2): 192-201.
10. Dogan A, Dogdu O, Ozdogru J, YarLiogLu M et aL. Cardiac effect of chronic graft-versus-host disease after steam ceLL transpLantation. Tex Heart Inst J. 2013. 40 (4): 428-434.
11. Ferrara J, Yanik G. Acute graft versus host disease: pathophysioLogy, risk factors, and prevention strategies. CLin Adv HematoL OncoL. 2005. 3 (5): 415-419, 428.
12. Ferrara J. NoveL strategies for the treatment and diagnosis of graft-versus-host-disease. Best Pract Res CLin HaematoL. 2007. 20 (1): 91-97.
13. HantzscheL I. Targeting mycophenoLate mofetiL for graft-versus-host disease prophyLaxis after aLLogenic bLood stem ceLL transpLantation. Dissertationsschrift zur ErLangung eines doctor medicinae (Dr. med.) der Medizinischen FakuLtat CarL Gustav Carus der Technischen Universitat Dresden. Dresden, 2010. 27 s.
14. Inagaki J, Fukano R, Kodama Y, Nishimura M et aL. Safety and efficacy of Low-dose methotrex-ate for pediatric patients with steroid-refractory acute graft-versus-host disease after hemat-opoietic stem ceLL transpLantation. Ann HematoL. 2014. 93 (4): 645-651.
15. Landero J, GreLck S, Nousari C. Graft-vesus-host disease. In: LebwohL M, Heymann W, Jones J, CouLson I. (Eds.) Treatment of skin diseases. Saunders. ELsevier 2014. p. 276-279.
16. Busca A, SarogLia E, Lanino E, Manfredini L et aL. MycophenoLate mofetiL (MMF) as therapy for refractory chronic GVHD (cGVHD) in chiLdren receiving bone marrow transpLantation. Bone Marrow Transplant. 2000. 25 (10): 1067-1071.
17. Saad A, ALyea E, Wen P. Graft-versus-host disease of the CNS after aLLogeinic bone marrow transpLantation. J. Clin. Oncol. 2009. 27 (30): e147-e149.
18. Harnicar St, Ponce D, HiLden P, Zheng J et aL. Intensified mycophenoLate mofetiL dosing and higher mycophenoLic acid throhg LeveLs reduce sevsre acute graft-versus-host disease after doubLe-unit cord bLood transpLantation. Biol Blood Marrow Transplant. 2015. 21 (5): 920-925.
19. Zhu X, Lai X, Luo Y, Shi J et aL. Combination of Low dose mycophenoLate mofetiL with cycLos-poeine and methotrexate as GVHD prophyLaxis in unreLated donor aLLogeinic stem ceLL transpLantation. Leukemia Research. 2013. 37 (9): 1046-1051.
20. Minagawa K, Yamamori M, Katayama Y, Matsui T, MycophenoLate mofetiL: fuLLy utiLizing its benefits for GvHD prophyLaxis. Int. J. Hematol. 2012. 96 (1): 10-25.
21. Skvortsova Y.V., Balashov D.N., Maschan M.A., Shelikhova L.N., Maschan A.A. Dynamic follow-up of children after allogeneic hematopoietic stem cell transplantation. Rossiyskiy Zhurnal Detskoy Gematologii i Onkologii, 2015. 2 (2): 50-59.
Review
For citations:
Skvortsova YV, Balashov DN, Delyagin VM. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in children. Meditsinskiy sovet = Medical Council. 2016;1(1):136-139. (In Russ.) https://doi.org/10.21518/2079-701X-2016-1-136-139
Views:
1293
Email this article 